外源性表面活性物质治疗COVID-19相关ARDS一例
本文报道一例COVID-19相关ARDS患者接受外源性表面活性物质治疗的经验。患者表现为与相对保留的肺力学不成比例的严重低氧血症,类似新生儿呼吸窘迫综合征的表面活性物质缺乏模式。治疗后氧合改善,作者认为表面活性物质是成功拔管和临床改善的催化剂。
要点
- COVID-19相关ARDS可表现为与肺力学保留不成比例的严重低氧血症。
- 该模式类似新生儿呼吸窘迫综合征的表面活性物质缺乏。
- 外源性表面活性物质治疗后该患者氧合改善并成功拔管。
核心结论
- 外源性表面活性物质治疗COVID-19相关ARDS患者后氧合改善,作者认为其是成功拔管和临床改善的催化剂。
研究设计与样本
- 本文为单例病例报告,报告一例COVID-19相关ARDS患者接受外源性表面活性物质治疗的经验。
主要发现
- 患者接受外源性表面活性物质治疗后氧合改善。
- 患者成功拔管并临床改善,作者认为表面活性物质是催化剂。
- COVID-19相关ARDS表现为与相对保留的肺力学不成比例的严重低氧血症。
临床怎么用
- 对COVID-19相关ARDS中表现为与肺力学保留不成比例低氧血症的患者,可考虑外源性表面活性物质治疗。
局限性
- 本文为单例病例报告,无法确立因果关系或普遍适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 exhibit a disproportionate hypoxemia compared with relatively preserved lung mechanics. This pattern is more similar to neonatal respiratory distress syndrome secondary to surfactant deficiency, which has been shown to benefit from exogenous surfactant. We present our experience with exogenous surfactant treatment in a patient with COVID-19 experiencing COVID-19-related ARDS. The patient responded with improved oxygenation, and we believe surfactant was the catalyst for the successful extubation and clinical improvement of the patient.
引用
- Heching M, Lev S, Shitenberg D, et al. Surfactant for the Treatment of ARDS in a Patient With COVID-19. Chest. 2021. PMID: 33493441. doi:10.1016/j.chest.2021.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。